Kryger Capital’s Amicus Therapeutics FOLD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-4,554,174
Closed -$65.9M 115
2026
Q1
$65.9M Buy
4,554,174
+1,559,774
+52% +$22.4M 4.66% 9
2025
Q4
$42.6M Buy
+2,994,400
New +$29.4M 3.29% 14

Other funds holding FOLD

Kryger Capital's FOLD Position: Q2 2026 in Review

Kryger Capital sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 4,554,174 shares — an estimated $65.9M sold.

Kryger Capital first reported a position in FOLD in Q4 2025 and held it in 2 quarters. The position peaked at $65.9M in Q1 2026. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

  • Kryger Capital reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Kryger Capital sold 4,554,174 Amicus Therapeutics shares in Q2 2026, an estimated $65.9M.
  • Kryger Capital first reported a position in Amicus Therapeutics in Q4 2025 and held it in 2 quarters.
  • Kryger Capital's Amicus Therapeutics position peaked at $65.9M in Q1 2026.
  • 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on Kryger Capital's 13F filing for Q2 2026, filed 14 Aug 2026.